|
Orthologous residues
|
|
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Disease tissue studied:
lymphoma, Burkitt's lymphoma
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), RAMOS (B lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anti-IgM
|
|
|
|
increase
|
|
|
t-butanol
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
transcription, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
RGS13 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
|
Comments:
RGS13 reduces CREB DNA binding affinity.
|
